Key result
IV nifekalant during CFAE ablation fails to improve 24-month atrial arrhythmia-free survival.
Why the study?
Does intravenous nifekalant improve 24-month atrial arrhythmia-free survival in patients with persistent atrial fibrillation undergoing first radiofrequency catheter ablation?
Cohort (n=157)
No
Does intravenous nifekalant improve 24-month atrial arrhythmia-free survival in patients with persistent atrial fibrillation undergoing first radiofrequency catheter ablation?
Intravenous nifekalant during RFCA for persistent AF increases intraprocedural AF termination but does not significantly improve long-term arrhythmia-free survival.
Answers are grounded in this paper and cite their sources.
Nifekalant should not yet change ablation practice for persistent AF; leaves open whether acute termination predicts long-term success in randomized trials.
BACKGROUND: Radiofrequency catheter ablation (RFCA) for persistent atrial fibrillation (AF) is still challenging even in RFCA-era for AF. The aim of this study was to assess the clinical utility of nifekalant, a pure potassium channel blocker,during RFCA for persistent AF. METHODS AND RESULTS: We retrospectively enrolled 157 consecutive persistentAF patientsundergoing first RFCA procedure withcomplex fractionated atrial electrogram (CFAE)ablation after pulmonary veins isolation and compared outcomes between patientswith (NFK group: N=79) and without (No-NFK group: N=78)additional CFAE ablation using intravenous nifekalant (0.3mg/kg). Primary endpoint was 24-month atrial arrhythmia-free survival post ablation.The prevalence of AF terminationwas significantly higher in NFK group than No-NFK group (64.6% versus 7.7%, P<0.001). Arrhythmia-free survival, however, was not significantly different between 2 groups (61.5% versus 54.1%, P=0.63).There was no significant difference between 2 groups in the prevalence of recurrent atrial tachycardia(25.0% versus 23.5%, P=0.89). Arrhythmia-free survivalin patients with AF termination during procedure was significantly higher thanthose without (73.0% versus 41.0%, P=0.002; adjusted hazard ratio 0.48, 95% confidence interval 0.17-0.84, P=0.02) amongNFK group,but not amongNo-NFK group (66.7% versus 53.2%, P=0.53). CONCLUSIONS: Intravenous nifekalant injection during additional CFAE ablation did not improve sinus maintenancerate after RFCA procedure for AF, but AF termination by nifekalant injection could be a clinical predictor of better success rates after procedure.
No takes yet. Share an insight, caveat, or question.
Tetsuma Kawaji (2018) conducted a cohort in Persistent Atrial Fibrillation (n=157). Intravenous nifekalant vs. No nifekalant was evaluated on 24-month atrial arrhythmia-free survival post ablation (p=0.63). Intravenous nifekalant injection during additional CFAE ablation did not improve 24-month atrial arrhythmia-free survival compared to no nifekalant.
Synapse has enriched 10 related papers. Consider them for comparative context: